Dexamethasone Intravitreal Implant Therapy for Retinal Vein Occlusion Macular Oedema and Conversion to Ranibizumab in Clinical Practice

2017 ◽  
Vol 239 (1) ◽  
pp. 36-44 ◽  
Author(s):  
Shafi Balal ◽  
Jonathan Than ◽  
Sharmila Tekriwal ◽  
Aires Lobo
Keyword(s):  
Clinical Practice ◽  
Retinal Vein Occlusion ◽  
Macular Oedema ◽  
Dexamethasone Intravitreal Implant ◽  
Vein Occlusion ◽  
Intravitreal Implant ◽  
Implant Therapy

scholarly journals Retrospective, Observational Study in Patients Receiving a Dexamethasone Intravitreal Implant 0.7 mg for Macular Oedema Secondary to Retinal Vein Occlusion

2014 ◽  
Vol 233 (1) ◽  
pp. 18-26 ◽  
Author(s):  
Albert J. Augustin ◽  
Frank G. Holz ◽  
Christos Haritoglou ◽  
Wolfgang J. Mayer ◽  
Silvia Bopp ◽  
...  
Keyword(s):  
Observational Study ◽  
Retinal Vein Occlusion ◽  
Macular Oedema ◽  
Routine Practice ◽  
Glaucoma Medication ◽  
Dexamethasone Intravitreal Implant ◽  
Vein Occlusion ◽  
Intravitreal Implant ◽  
Injection Interval ◽  
Mean Time

Purpose: To retrospectively evaluate the re-injection interval, efficacy and safety of dexamethasone (DEX) intravitreal implant 0.7 mg in the treatment of macular oedema (ME) due to retinal vein occlusion (RVO) in Germany in 2009-2012. Methods: Retrospective, multicentre, anonymised observational study of data collected from the first DEX implant 0.7 mg injection through 3-6 months following the last injection. Data were included if the patient was >18 years old, had a diagnosis of ME secondary to branch or central RVO, and received at least 2 DEX implant 0.7 mg injections during routine practice. Results: Data from 87 patients were analysed. Mean time to re-injection between first and second treatments was 5.03 months in the total RVO population, and 5.46 and 4.52 months for the branch and central RVO subpopulations, respectively. An intraocular pressure increase of >25 mm Hg was recorded in 20% of patients, and 34% of patients began treatment with anti-glaucoma medication, but surgery was not needed for this condition. Conclusions: DEX implant 0.7 mg was found to be well tolerated and effective with repeat treatments in clinical practice.

scholarly journals Macular hole after injection of dexamethasone intravitreal implant for macular oedema due to central retinal vein occlusion

2012 ◽  
Vol 91 (1) ◽  
pp. e75-e77 ◽  
Author(s):  
Umberto De Benedetto ◽  
Maurizio Battaglia Parodi ◽  
Karl Anders Knutsson ◽  
Rosangela Lattanzio ◽  
Francesco Bandello ◽  
...  
Keyword(s):  
Macular Hole ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Macular Oedema ◽  
Dexamethasone Intravitreal Implant ◽  
Vein Occlusion ◽  
Intravitreal Implant ◽  
Central Retinal Vein

Dexamethasone intravitreal implant downregulates PDGFR-α and upregulates caveolin-1 in experimental branch retinal vein occlusion

2018 ◽  
Vol 171 ◽  
pp. 174-182 ◽  
Author(s):  
Lasse Jørgensen Cehofski ◽  
Anders Kruse ◽  
Sigriður Olga Magnusdottir ◽  
Alexander Nørgård Alsing ◽  
Jonas Ellegaard Nielsen ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Caveolin 1 ◽  
Dexamethasone Intravitreal Implant ◽  
Vein Occlusion ◽  
Intravitreal Implant
Sign in / Sign up

Export Citation Format

Share Document